Nahla Aris-Jilwan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar state.

Jean‐Louis Chiasson, Nahla Aris-Jilwan, Raphaël Bélanger et al. · PubMed · 2003 · 291 citations

Medicine, Endocrinology, Internal Medicine +17

The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas

R Comtois, Hugues Beauregard, M Somma et al. · Cancer · 1991 · 258 citations · Full text

Medicine, Endocrinology, Surgery +17

The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events

F Mindlen, Roberto Nordaby, M I Soto Ruiz et al. · Queensland's institutional digital repository (The University of Queensland) · 1996 · 154 citations

Medicine, Cardiology, Pharmacotherapy +17